Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Trial Profile

A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs BAY 1093884 (Primary)
  • Indications Haemophilia
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 21 Dec 2019 Planned End Date changed from 13 Dec 2018 to 13 Feb 2019.
    • 24 Oct 2018 Planned End Date changed from 9 Nov 2018 to 13 Dec 2018.
    • 28 Sep 2018 Planned primary completion date changed from 30 Sep 2018 to 19 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top